sorafenib has been researched along with salvigenin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (salvigenin) | Trials (salvigenin) | Recent Studies (post-2010) (salvigenin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 27 | 0 | 19 |
| Protein | Taxonomy | sorafenib (IC50) | salvigenin (IC50) |
|---|---|---|---|
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.4733 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, LC; Hsu, KC; Huang, HL; Huang, WJ; Lien, ST; Lin, TE; Ngo, ST; Pan, SL; Sung, TY; Tseng, HJ; Wu, YW; Yen, SC | 1 |
1 other study(ies) available for sorafenib and salvigenin
| Article | Year |
|---|---|
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Apoptosis; Flavonoids; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2021 |